Leyden Labs has secured €20 million in financing from the European Investment Bank (EIB), supported by HERA Invest under the EU’s InvestEU programme.
The funding will support the clinical development of Leyden Labs’ PanFlu nasal spray, an intranasal antibody therapy designed to protect against a broad range of influenza viruses, including seasonal flu, avian flu (H5), and future respiratory threats. Unlike traditional vaccines, this approach offers direct, fast-acting protection at the site of infection: the respiratory mucosa.
With this investment, Leyden Labs takes a major step forward in preparing for future pandemics through scalable, accessible prevention strategies that complement existing vaccine efforts.
Read more here
Last week, demissionary Minister of Social Affairs and Employment Eddy van Hijum paid a visit last week to the Post-COVID Expertise Center at Leiden University Medical Center...
Looking for something thoughtful to tune into this summer? Biopolis – Into the Microbiome is a new science podcast blending documentary storytelling with fiction to explore the...
Leiden Bio Science Park is taking concrete steps to increase biodiversity across its grounds, moving beyond ornamental landscaping to create habitats that support a wide range of...